Tempus RWE

An AI-enabled platform leveraging the world's largest library of multimodal clinical and molecular data to generate Real-World Evidence (RWE) for drug discovery and clinical trial optimization.

https://www.tempus.com

Overview

Tempus RWE is a core offering of the Tempus AI platform, designed specifically for life sciences and biopharma organizations to accelerate the discovery, development, and delivery of optimal therapeutics. The platform integrates one of the world's largest libraries of multimodal data, which includes DNA and RNA molecular data, clinical data (including outcomes), and imaging data, sourced from millions of de-identified research records.

Key Capabilities & Value Proposition

Tempus RWE uses AI and machine learning to transform this complex, heterogeneous data into actionable Real-World Evidence (RWE). This evidence is used to:

Optimize Clinical Trial Design: By applying RWE dataset analyses, Tempus helps increase the Probability of Technical Success (PTS) of studies, informing critical go/no-go decisions for Phase 3 trials and refining inclusion/exclusion criteria.
Generate External Control Arms (ECA): For single-arm Phase 2 studies, the platform can create robust synthetic or external control arms to contextualize the efficacy of experimental treatments.
Accelerate Drug Discovery: The multimodal data and AI analytics are used to gather biological and clinical insights, discover novel drug targets, and develop therapeutics for the broader oncology community.
Companion Diagnostic Development: The platform helps identify patients who will benefit most from a treatment by providing a molecular view of tumors and using analytical tools to select the right patients.

Target Users and Market

The primary target market is **Enterprise Biopharma** and **Life Sciences** companies, including major pharmaceutical organizations (e.g., AstraZeneca, Pfizer, GSK, BioNTech) that are engaged in oncology and other complex disease R&D. The service is a high-value, collaborative, and custom-solution model, not a self-service software product with public pricing.

Key Features

- Multimodal Data Library (Genomic, Clinical, Imaging)
- AI/ML-Driven Real-World Evidence (RWE) Generation
- Clinical Trial Design Optimization (PTS Increase)
- External Control Arm (ECA) Generation
- Novel Drug Target Discovery and Validation
- Companion Diagnostic Development Support
- EHR Integration (via Tempus Platform)

Pricing

Model: enterprise

Pricing is not publicly disclosed and is based on custom, multi-year strategic collaborations and data licensing agreements with enterprise biopharma partners. Deals often involve large, multi-million dollar contracts.

Target Company Size: enterprise

Integrations

Biopharma R&D Pipelines (e.g., AstraZeneca, GSK, Pfizer), Electronic Health Record (EHR) Systems

Compliance & Certifications

HIPAA, GDPR, ISO 27001